Recursion Pharmaceuticals, Inc. $RXRX Shares Acquired by Commons Capital LLC

Commons Capital LLC lifted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 7.7% during the second quarter, Holdings Channel reports. The firm owned 117,522 shares of the company’s stock after purchasing an additional 8,426 shares during the quarter. Commons Capital LLC’s holdings in Recursion Pharmaceuticals were worth $595,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. AlphaQuest LLC purchased a new position in Recursion Pharmaceuticals in the 1st quarter worth about $36,000. GAMMA Investing LLC increased its position in shares of Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after acquiring an additional 2,026 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $51,000. ADG Wealth Management Group LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $55,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Recursion Pharmaceuticals in the 1st quarter worth approximately $57,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Insider Buying and Selling

In other news, insider Najat Khan sold 36,599 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.52, for a total transaction of $202,026.48. Following the transaction, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This trade represents a 5.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.43% of the stock is owned by corporate insiders.

Recursion Pharmaceuticals Price Performance

RXRX opened at $6.36 on Friday. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.02. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The stock has a fifty day moving average price of $5.12 and a 200 day moving average price of $5.12. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -3.57 and a beta of 0.91.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The firm had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. During the same period in the previous year, the firm posted ($0.40) EPS. The company’s quarterly revenue was up 33.3% compared to the same quarter last year. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on RXRX. Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Morgan Stanley began coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $7.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.